Central Bank & Trust Co. Has $2.03 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Central Bank & Trust Co. trimmed its stake in shares of Danaher Co. (NYSE:DHR) by 0.9% during the third quarter, Holdings Channel reports. The firm owned 7,308 shares of the conglomerate’s stock after selling 69 shares during the period. Central Bank & Trust Co.’s holdings in Danaher were worth $2,032,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of DHR. Benjamin Edwards Inc. grew its position in Danaher by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after acquiring an additional 38 shares during the period. Wedge Capital Management L L P NC grew its holdings in shares of Danaher by 3.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares during the last quarter. Patrick M Sweeney & Associates Inc. increased its position in shares of Danaher by 3.4% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after purchasing an additional 40 shares in the last quarter. Trust Co of Kansas lifted its holdings in Danaher by 4.1% during the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after purchasing an additional 40 shares during the last quarter. Finally, Abacus Planning Group Inc. boosted its position in Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after buying an additional 40 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.90% of the stock is owned by insiders.

Danaher Stock Performance

Shares of NYSE DHR opened at $247.18 on Tuesday. The stock has a market capitalization of $178.53 billion, a PE ratio of 47.17, a price-to-earnings-growth ratio of 4.55 and a beta of 0.85. Danaher Co. has a 52 week low of $192.35 and a 52 week high of $281.70. The stock has a 50 day moving average price of $266.53 and a 200 day moving average price of $260.74. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the company earned $2.02 earnings per share. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. Analysts predict that Danaher Co. will post 7.51 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s dividend payout ratio is 20.61%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on DHR. UBS Group reduced their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. The Goldman Sachs Group upped their price target on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Robert W. Baird lowered their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Wells Fargo & Company initiated coverage on Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target on the stock. Finally, Bank of America lifted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Six analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.